Seattle, WA -- (SBWIRE) -- 09/23/2019 -- Multiple myeloma (MM) refers to a clonal plasma cell malignant neoplasm that is observed in the soft, spongy tissue of the bone marrow. The plasma cells are a vital part of the immune system and aid in preventing several types of infections and other diseases. MM is a result of formation of malignant plasma cells and is characterized by low blood counts, renal failure, hypercalcemia, immune suppression, monoclonal gammopathy, and anemia. A completely effective cure for MM is yet to be found. According to the American Cancer Society, in 2017, an estimated 30,280 adults (17,490 men and 12,790 women) in the U.S. will be diagnosed with MM and 12,590 deaths (6,660 men and 5,930 women) will occur in U.S. in 2017 due to the disease. According to the National Center for Biotechnology Information 2014, MM represents 8.2% of all blood cancers in Africa.
B-Cell maturation antigen (BCMA) is a cell surface protein that is expressed on the malignant plasma cells. The expression profiles exhibited by TACI and BAFF-R are comparatively lower compared to that of BCMA in MM patients. Moreover, these antigens are hard to be detected in the malignant plasma cells. Therefore, BCMA is a most preferred choice over other targeting antigens. The expression of BCMA increases as the condition progresses from normal Monoclonal Gammopathy of Undetermined Significance (MUGA) to smoldering multiple myeloma (SMM) to active multiple myeloma. The BCMA cells demonstrate this rare expression profile, owing to their restricted expression pattern. BCMA cells are not expressed in normal human tissues. These properties have led to increasing adoption of BCMA-target therapies for the treatment of cancers such as multiple myeloma. BCMA has co-immunoprecipitation property with a master transcription factor (IRF-4) that are mediated for myeloma cell survival. BCMA targeted therapies can be divided into three major types based on product class: chimeric antigen receptor T-cells (CAR T Cells), bispecific antibodies, and antibody drug conjugates (ADCs).
Get HOLISTIC Request Sample Copy:https://www.coherentmarketinsights.com/insight/request-sample/190
However, high cost involved in multiple combinational drug as well as maintenance therapy in BCMA-targeted therapy is expected to hinder the market growth.
Key players in the market are focused on product development and preclinical and clinical trials. Results on BCMA-targeted therapies have demonstrated potential benefits, mainly through the safety profile offered by these therapies.
Increasing number of pipeline products is expected to boost growth of the BCMA targeted therapies market
Key players in the market are focused on investing in R&D activities and introduction of novel therapies to expand their product portfolio. These therapies include, chimeric antigen receptor T cells, antibody-drug conjugate, and Bi-specific antibodies. For instance, GlaxoSmithKline Plc. (GSK2857916) is developing the antibody conjugate drug with relapsed/refractory multiple myeloma and other advanced hematologic malignancies expressing BCMA. Therefore, increasing number of pipeline drugs for the treatment of multiple myeloma is expected to propel growth of the B-cell maturation Antigen (BCMA) targeted therapies market.
Increasing prevalence of multiple myeloma is expected to drive growth of the B-cell maturation antigen (BCMA) targeted therapies market.
Buy This Business Report:https://www.coherentmarketinsights.com/insight/buy-now/190
Key Features of the Study:
This report provides in-depth analysis of the global B-cell maturation antigen (BCMA) targeted therapies market and provides pipeline analysis for the same
It elucidates potential opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, impact analysis, key developments, and competitive landscape
It profiles leading players in the global B-cell maturation antigen (BCMA) targeted therapies market based on the following parameters – company overview, financial performance, product pipeline, geographical presence, and key developments
Key companies covered as a part of this study include Celgene Corporation, GlaxoSmithKline plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future BCMA targeted therapies product launch, market expansion, and marketing tactics
The global BCMA targeted therapies market report caters to various stakeholders in this industry including, investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the B-Cell maturation antigen (BCMA) targeted therapies market
Browse For More Information:https://www.coherentmarketinsights.com/market-insight/bcma-targeted-therapies-market-190
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
The patients that adopt chemotherapy and radiation therapy may develop resistance to these therapies, which can increase the risk of recurrence of cancer. Currently, no therapy is available for patients with recurrent cancer. Therefore, BCMA targeted therapies are a potential option for the treatment of relapsed or refractory multiple myeloma. This therapy is expected to cater to current unmet needs for the treatment of relapsed or refractory myeloma, where the existing therapies have failed to offer better outcome.
Key players operating in the B-cell maturation antigen (BCMA) targeted therapies market are Celgene Corporation, GlaxoSmithKline plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd.